{"prompt": "['APPROVED: Oct 30, 2017', 'COPERNICUS GROUP IRB', 'HEALTH OUTCOMES STUDY PROTOCOL - QUALITATIVE RESEARCH', 'UNIQUE IDENTIFIER', 'HO-16-17264', 'FULL TITLE', 'Qualitative research to characterize the patient', 'experience of nasal polyps', 'ABBREVIATED TITLE', 'Qualitative research to categorize nasal polyps', 'FINAL PROTOCOL', 'DD-MMM-YYYY', 'APPROVED', '(Enter date of Senior Line Manager approval signature)', 'SPONSORSHIP', 'Sponsored or Supported', 'DIVISION', 'Pharma', 'BUSINESS UNIT', 'Research & Development', 'DEPARTMENT', 'VEO', 'STUDY ACCOUNTABLE', 'PPD', 'PERSON', 'CONTRIBUTING AUTHORS', 'PPD', '(GSK), PPD', '(GSK), PPD', '(Adelphi Values),', 'PPD', '(Adelphi Values) and', 'PPD', '(Adelphi Values)', 'ASSET ID', 'SB240563', 'GSK ASSET', 'Mepolizumab', 'INDICATION', 'Nasal Polyps', 'REVISION CHRONOLOGY:', 'Version Date', 'Document', 'Change(s) since last version', 'Type', '14/02/2017', 'Original', 'n/a', '(V1_0)', '13/04/2017', 'V2_0', 'Comments from client incorporated', '02/05/2017', 'V3_0', 'Protocol transferred in GSK template as per', 'client request', 'CGI-501 E010', 'Page 1 of 131', 'Effective: 20 Jan 2017']['10/05/2017', 'V4_0', 'Client comments on update template', 'addressed for client internal review', 'committee', '25/05/2917', 'V5_0', 'Comments from client internal review', 'committee addressed', '12/06/2017', 'V6_0', 'Version approved by client internal review', 'committee and version submitted to IRB', '30/10/2017', 'V7_0', 'Errors with study quotas corrected and', 'study quotas broadened to allow for', 'smoother recruitment.', 'New exclusion criteria added to ensure', 'that the criteria was aligned with that', \"of the client's clinical trial.\", 'Interview length extended to 120 mins', 'and incentive increased to $200 to', 'ensure that all concepts could be', 'covered in interviews.', 'Description: Qualitative research to categorize nasal polyps', 'Unique Identifier: HO-16-17264', 'SPONSOR SIGNATORY', 'DD-MMM-YYYY', \"Enter Sponsor Signatory's name\", 'Date', 'Senior Line Manager', 'Enter title, e.g. Therapy Area Head, Senior Group', 'Leader, or Medical Director', 'GK7818Av7_0', 'Page 2 of 131', 'Effective: 20 Jan 2017']['Only include this section if the study uses study sites to collect data.', 'Description: Abbreviated Title', 'Unique Identifier: trackHO/eTrack ID', 'Investigator Protocol Agreement Page', 'I confirm agreement to conduct the study in compliance with the protocol.', 'I acknowledge that I am responsible for overall study conduct. I agree to', 'personally conduct or supervise the described clinical study.', 'I agree to ensure that all associates, colleagues and employees assisting in the', 'conduct of the study are informed about their obligations. Mechanisms are in', 'place to ensure that site staff receives the appropriate information throughout the', 'study.', 'Investigator Name:', 'Investigator Signature', 'Date (DD-MMM-', 'YYYY)', 'GK7818Av7_0', 'Page 3 of 131', 'Effective: 20 Jan 2017']\n\n###\n\n", "completion": "END"}